OraSure Technologies (FRA:EP3) Tax Provision : €-2.6 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is OraSure Technologies Tax Provision?

OraSure Technologies's tax provision for the three months ended in Mar. 2024 was €0.0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.6 Mil.

OraSure Technologies Tax Provision Historical Data

The historical data trend for OraSure Technologies's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies Tax Provision Chart

OraSure Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-4.21

-9.37

-12.13

-1.38

-2.39

OraSure Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															0.21	0.15	-2.20	-0.59	0.02

OraSure Technologies Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.6 Mil.

OraSure Technologies (FRA:EP3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (FRA:EP3) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

OSUR:USA

Address

220 East First Street, Bethlehem, PA, USA, 18015

Website

https://www.orasure.com

OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.

OraSure Technologies (FRA:EP3) Headlines

No Headlines